twit 25   linkedin 25

17 / May 02

Financial communication - Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

The agreement includes Celyad’s intellectual property rights under United States Patent No. 9,181,527 related to allogeneic human primary T-Cells that are engineered to be T-Cell Receptor (TCR) deficient and express a Chimeric Antigen Receptor (CAR). The granted claims are not limited to specific CARs or specific methods of generating allogeneic CAR Tcells, such as genome editing or genetic engineering.
 
Under the terms of the agreement Celyad receives an upfront payment and is eligible to receive success based clinical, regulatory and commercial milestone payments. If all success based milestones are achieved, Celyad is eligible to receive payments, including the upfront payment, totalling $96 million. In addition, Celyad will receive single digit royalties based on
net sales of the licensed target associated products. Novartis has the option to extend the agreement to additional targets and/or to convert its license into an exclusive license. Celyad
retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

About NewCap

As a specialist in investor relations and strategic communication advice, NewCap advises and supports its clients regarding their sectoral, scientific, institutional and financial communication strategies.

CONTACT

contact 01Address :
21, place de la Madeleine - 75008 Paris

contact 02Phone :
+33 (0)1 44 71 94 94

contact 03Email :
infos(at)newcap.fr